Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer
نویسندگان
چکیده
منابع مشابه
FDA approves regorafenib (Stivarga) for metastatic colorectal cancer.
“Stivarga is the latest colorectal cancer treatment to demonstrate an ability to extend patients’ lives, and is the second drug approved for patients with colorectal cancer in the past 2 months,” said Richard Pazdur, MD, director of the office of hematology and oncology products in FDA’s Center for Drug Evaluation and Research, in a press release. In August, the FDA approved aflibercept (Zaltra...
متن کاملEfficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice
BACKGROUND Regorafenib is an orally administered multikinase inhibitor that has been approved for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). Even though regorafenib significantly improved survival in two international phase 3 trials (CORRECT and CONCUR), a high rate of treatment-related toxic effects and dose modifications were observed with a modest benefit. The...
متن کاملRe: Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.
We read with interest the article by Behl and colleagues regarding the cost-effectiveness of screening for mutations in metastatic colorectal cancer (1). As researchers in the field, we greatly appreciate the Journal’s interest in publishing cost analyses because it is very important to promote outcomes research for evidence-based decision making. We may agree with the findings that KRAS and BR...
متن کاملCost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.
BACKGROUND In 2009, the American Society of Clinical Oncology recommended that patients with metastatic colorectal cancer (mCRC) who are candidates for anti-epidermal growth factor receptor (EGFR) therapy have their tumors tested for KRAS mutations because tumors with such mutations do not respond to anti-EGFR therapy. Limiting anti-EGFR therapy to those without KRAS mutations will reserve trea...
متن کاملScreening for Colorectal Cancer: Analysis of Evidence and Cost-Effectiveness
Colorectal cancer causes significant morbidity and mortality and remains the second most common cause of cancer-related death in the United States. A number of screening approaches have been shown to decrease colon cancer–related mortality and are cost-effective. In this review, we discuss available screening approaches and suggest strategies to implement effective screening using the current t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Oncology
سال: 2015
ISSN: 0732-183X,1527-7755
DOI: 10.1200/jco.2015.61.9569